This content is from: United Kingdom

AstraZeneca on hindsight in the valuation of intangibles

The OECD is considering the use of hindsight when tax authorities are assessing hard-to-value intangibles (HTVI). Ian Brimicombe, VP of corporate finance at AstraZeneca in the UK, discusses the impact on taxpayers.

To access our market-driven intelligence please request a trial here.

Read this article – and more – for a 30 day period.


Are you already an ITR subscriber? Log in here

Instant access to all of our content. Membership Options | 30 Day Trial